Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dubermatinib - Sumitomo Pharma America

Next Previous
Drug Profile

Dubermatinib - Sumitomo Pharma America

Alternative Names: TP-0903

Latest Information Update: 19 Jul 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tolero Pharmaceuticals
  • Developer Sumitomo Pharma America; Tolero Pharmaceuticals
  • Class Aniline compounds; Antineoplastics; Piperazines; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action Aurora kinase B inhibitors; Axl receptor tyrosine kinase inhibitors; Janus kinase 2 inhibitors; STAT6 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Chronic lymphocytic leukaemia
  • Phase I Solid tumours
  • Preclinical Breast cancer; Malignant melanoma
  • No development reported Glioblastoma; Head and neck cancer; Lung cancer; Neuroblastoma

Most Recent Events

  • 08 Jun 2023 Efficacy and adverse events data from a phase Ib/II Beat AML trial in Acute myeloid leukemia presented at the 28th Congress of the European Haematology Association (EHA-2023)
  • 14 Apr 2023 Dubermatinib is still in preclinical phase trials for breast cancer in USA
  • 14 Apr 2023 Pharmacodynamics data from preclinical studies in breast cancer presented at 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top